Advertisement

Reteplase Injection

[16 April 2014]

Products Affected - Description

Retavase Injection, Cornerstone Therapeutics (formerly EKR Therapeutics)
Half Kit, one 10.4 unit single use vial (NDC 24477-0040-01)
Full Kit, two 10.4 unit single use vials (NDC 24477-0041-02)

Reason for the Shortage

Cornerstone Therapeutics acquired EKR Therapeutics in June 2012. EKR Therapeutics had previously purchased Retavase from PDL BioPharma. Cornerstone is seeking FDA approval of a new supplier of the active pharmaceutical ingredient for Retevase.

Available Products

No presentations are available.

Estimated Resupply Dates

Cornerstone Therapeutics has Retavase on long-term back order and the company cannot estimate a release date.

Related Shortages

Updated

April 16, 2014; January 14, 2014; October 15, 2013; August 5, 2013; June 13, 2013; April 12, 2013; January 16, 2013; October 19, 2012; July 19, 2012; April 5, 2012; January 4, 2012; October 12, 2011; August 2, 2011; May 3, 2011; February 28, 2011; February 14, 2011; February 3, 2011; December 10, 2010; October 6, 2010; July 30, 2010; May 28, 2010; March 30, 2010; February 10, 2010; January 20, 2010; January 5, 2010; December 15, 2009; November 25, 2009; November 24, 2009; November 18, 2009; November 10, 2009; October 9, 2009, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement